Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (1) BJPS (1) Autor Araujo,D.V. (1) Chammas,R. (1) Fernandes,G.S. (1) Gifoni,M.A.C. (1) Gil,R.A. (1) Lopes,G. (1) Monteiro,Gisele (1) Pimenta,Marcela Valente (1) Sternberg,C. (1) Mais... Palavra-chave Biosimilar (2) Access (1) Biological drugs (1) Biopharmaceutical (1) Brazilian biopharmaceutical market (1) Cancer management (1) Immunobiologicals (1) Therapeutic antibodies (1) Mais... Tipo do documento Info:eu-repo/semantics/article (1) Info:eu-repo/semantics/other (1) Ano 2019 (1) 2018 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última The production of biopharmaceuticals in Brazil: current issues BJPS Pimenta,Marcela Valente; Monteiro,Gisele. Biopharmaceuticals are gaining a growing share of the pharmaceuticals market. In recent years, the Brazilian Health Surveillance Agency (ANVISA) has approved the registration of biological drugs with domestic production. Although Brazil is in the early stages of biopharmaceutical production, governmental incentives and the investment in private companies in the technological domain in this country have created expectations of an increase in the capacity of biopharmaceutical production. Private initiatives, once rare, have now started to blossom in this field, such as collagenase from Cristalia and filgrastim from Eurofarm. The expiry of the patents for certain biopharmaceuticals (e.g. infliximab, filgrastim and rituximab) has generated the possibility of... Tipo: Info:eu-repo/semantics/article Palavras-chave: Biopharmaceutical; Biosimilar; Biological drugs; Brazilian biopharmaceutical market. Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100599 The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC) BJMBR Fernandes,G.S.; Sternberg,C.; Lopes,G.; Chammas,R.; Gifoni,M.A.C.; Gil,R.A.; Araujo,D.V.. A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the manufacturing process of which hinders the ability to identically replicate the structure of the original product, and therefore, it cannot be described as an absolute equivalent of the original medication. The currently available technology does not allow for an accurate copy of complex molecules, but it does allow the replication of similar molecules with the same activity. As biosimilars are about to be introduced in oncology practice, these must be evaluated through evidence-based medicine. This manuscript is a position paper, where the Brazilian Society of Clinical Oncology (SBOC) aims to describe pertinent issues regarding the approval and use of... Tipo: Info:eu-repo/semantics/other Palavras-chave: Immunobiologicals; Therapeutic antibodies; Biosimilar; Cancer management; Access. Ano: 2018 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000300401 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco